Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 13

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 13
---
 of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in or incorporated by reference into this prospectus supplement, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in and incorporated by reference into this prospectus supplement. In addition, even if our results of operations, financial condition, liquidity, prospects and the development of the industry in which we operate are consistent with the forward-looking statements contained in and incorporated by reference into this prospectus supplement, they may not be predictive of results or developments in future periods.

Actual results could differ materially from our forward-looking statements due to a number of factors, including risks related to:

| ● | our cash balances and our ability to obtain additional financing in the future; |

| ● | the success and timing of our ongoing and planned clinical trials and preclinical studies, including our ability to enroll participants in our studies at anticipated rates and our ability to manufacture an adequate amount of drug supply for our studies; |

| ● | obtaining and maintaining intellectual property protection for our current or future product candidates and our proprietary technology; |

| ● | the performance of third parties, including contract research organizations, manufacturers, suppliers, and outside consultants, to whom we outsource certain operational, staff and other functions; |

| ● | our ability to obtain and maintain regulatory approval of our current or future product candidates and, if approved, our products, including the labeling under any approval we may obtain; |

| ● | our plans and ability to develop and commercialize our current or future product candidates and the outcomes of our research and development activities; |

| ● | our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing; |

| ● | our future obligations under our license agreement with Vertex Pharmaceuticals Incorporated; |

| ● | our failure to recruit or retain key scientific or management personnel or to retain our executive officers; |

| ● | the accuracy of our estimates of the size and characteristics